Table 3 Risk factors for death in candidemic patients, according ICU vs non-ICU setting

Age

70 (55–74)

62 (53–73)

0.10

66 (53–73)

59 (52–70)

0.14

73 (68–76)

64 (53–74)

0.12

 Heart disease

42 (91%)

117 (80%)

0.09

30 (94%)

46 (90%)

0.57

12 (86%)

71 (75%)

0.40

 Respiratory disease

11 (24%)

20 (14%)

0.10

9 (28%)

11 (22%)

0.50

2 (14%)

9 (9%)

0.60

 Renal failure

32 (70%)

42 (29%)

< 0.001

25 (78%)

26 (51%)

0.02

7 (50%)

16 (17%)

0.008

 Liver disease

7 (15%)

12 (9%)

0.20

6 (19%)

6 (12%)

0.38

1 (7%)

7 (7%)

1.00

 Central nervous system disease

11 (24%)

19 (13%)

0.08

8 (25%)

6 (12%)

0.12

3 (21%)

13 (14%)

0.40

 Diabetes

15 (34%)

34 (23%)

0.20

11 (34%)

12 (24%)

0.28

4 (29%)

22 (23%)

0.70

 Solid organ transplant

4 (9%)

5 (3%)

0.15

4 (13%)

2 (4%)

0.16

0 (0%)

3 (3%)

–

 Solid cancer

9 (20%)

32 (22%)

0.70

5 (16%)

12 (24%)

0.39

5 (36%)

23 (24%)

0.40

 Onco-hematological disease

1 (2%)

9 (6%)

0.30

0 (0%)

1 (2%)

–

1 (7%)

8 (8%)

0.90

 Neutropenia

2 (4%)

9 (6%)

0.60

0 (0%)

0 (0%)

–

2 (14%)

(9%)

0.60

 Inflammatory disease

6 (13%)

15 (10%)

0.60

3 (9%)

4 (8%)

0.81

3 (21%)

11 (12%)

0.30

 Immunosuppression

4 (9%)

6 (4%)

0.20

3 (9%)

2 (4%)

0.32

1 (7%)

4 (4%)

0.60

 Pancreatitis

2 (4%)

9 (6%)

0.60

0 (0%)

3 (6%)

–

2 (14%)

6 (6%)

0.30

 Bacterial co-infection

41 (89%)

99(68%)

0.007

30 (94%)

40 (78%)

0.08

11 (79%)

59 (62%)

0.20

 Septic shock concomitant to candidemia

27 (59%)

28 (19%)

< 0.001

18 (56%)

13 (25%)

0.008

9 (64%)

15 (16%)

< 0.001

 SAPS2

NA

NA

NA

62 (43–75)

48 (40–66)

0.14

NA

NA

NA

 Intensive care Unit

35 (76%)

62 (42%)

< 0.001

NA

NA

NA

NA

NA

NA

 Extra renal epuration

24 (52%)

20 (14%)

< 0.001

20 (63%)

16 (31%)

0.006

4 (29%)

4 (4%)

0.005

 Invasive mechanical ventilation

31 (67%)

44 (30%)

< 0.001

29 (91%)

40 (78%)

0.16

2 (14%)

4 (4%)

0.15

 Central venous catheter

42 (91%)

128 (88%)

0.60

31 (97%)

49 (96%)

0.85

11 (79%)

79 (84%)

0.60

 CVC ablation

33 (72%)

108 (74%)

0.80

25 (78%)

44 (86%)

0.34

8 (57%)

64 (67%)

0.50

 Delay between the first day of candidemia and CVC ablation

2 (0–5)

2 (1–4)

0.60

2 (0–3)

2 (1–4)

0.34

5 (2–6)

2 (1–3)

1.00

 Total parenteral nutrition

21 (46%)

56 (39%)

0.40

15 (47%)

23 (45%)

0.87

6 (43%)

33 (35%)

0.60

 Antiacids

38 (83%)

118 (81%)

0.80

27 (84%)

41 (80%)

0.65

11 (79%)

77 (81%)

0.80

 Urinary catheter

40 (87%)

97 (67%)

0.01

30 (94%)

47 (92%)

1.00

11 (71%)

50 (53%)

0.20

 Surgery before candidemia

18 (39%)

71 (49%)

0.30

14 (44%)

31 (61%)

0.22

4 (29%)

40 (42%)

0.30

 Antifungal prophylaxis

6 (13%)

14 (10%)

0.50

5 (16%)

3 (6%)

0.16

1 (7%)

11 (12%)

0.60

 Delay of introduction of antifungal therapy

1 (0–2)

2 (0–2)

0.50

1 (−1–2)

2 (0–3)

0.04

2 (1–2)

2 (0–2)

0.60

 Antibiotics

44 (96%)

130 (89%)

0.20

31 (97%)

48 (94%)

0.57

13 (93%)

82 (86%)

0.50

 Number of antibiotics

4 (2–5)

2 (1–3)

< 0.001

4 (3–5)

3 (2–4)

0.04

2 (1–3)

2 (1–3)

0.14

 Leucocytes (.10³ /mm³)

18 (10–29)

13 (8–20)

0.009

21 (12–31)

19 (13–26)

0.61

12 (7–28)

10 (7–17)

0.11

 CRP (mg/L)

208 (108–305)

152 (87–246)

0.04

167 (80–306)

186 (113–244)

0.59

212 (145–282)

141 (69–247)

0.03

 PCT (μg/L)

9 (2–40)

3 (1–9)

0.20

8 (2–19)

3 (1–11)

0.18

48 (43–52)

2 (0–6)

0.30

 Β-D-glucan (pg/mL)

249 (126–1056)

85 (20–277)

0.40

251 (140–1065)

52 (14–236)

0.47

190 (69–2127)

111 47–451)

0.60

 C. albicans

30 (65%)

84 (58%)

20 (63%)

33 (65%)

10 (71%)

51 (54%)

 C. glabrata

5 (11%)

26 (18%)

0.20

3 (9%)

9 (18%)

0.41

2 (14%)

17 (18%)

0.60

 C. parapsilosis

1 (2%)

18 (12%)

0.08

1 (3%)

3 (6%)

0.62

0

15 (16%)

–

 C. tropicalis

1 (2%)

5 (3%)

0.60

1 (3%)

3 (6%)

0.62

0

2 (2%)

–

 C. krusei

3 (7%)

3 (2%)

0.20

3 (9%)

0 (0%)

–

0

3 (3%)

–